(Q34594440)

3 August 2017

1 reference

title

Dofetilide: a new class III antiarrhythmic agent. (English)

1 reference

3 August 2017

Henri Roukoz

1

1 reference

3 August 2017

Walid Saliba

series ordinal

2

1 reference

3 August 2017

publication date

1 January 2007

1 reference

Expert Review of Cardiovascular Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

5

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

9-19

1 reference

Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Evidence for gender differences in electrophysiological properties of canine Purkinje fibres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Effect of dofetilide on the pharmacokinetics of digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Azimilide dihydrochloride, a novel antiarrhythmic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.1.9

21 January 2018

Identifiers

DOI

10.1586/14779072.5.1.9

1 reference

3 August 2017

1 reference